



FIG. 1



Dose-Dependent Increase in Peak Flow Velocity Caused by CVT-3146



CVT-3146 and Coronary Flow Velocity


Duration of Effect:

Duration ≥ 2.5 Baseline	
Dose (n)	Mean \pm SEM
10 μg (4)	0
30 μg (4)	0
100 μg (3)	0.2 \pm 0.2 minutes
300 μg (4)	2.2 \pm 1.3 minutes
400 μg (8)	2.8 \pm 0.8 minutes
500 μg (4)	2.9 \pm 1.3 minutes


Figure 3

4/17

Time Course of APV Ratio (CVT-3146 400 μ g)



5/17



6/17

Time Course of Blood Pressure (CVT-3146 400 μ g)




Figure 6

7/17

All Drug-Related Adverse Events Were Mild and Transient


Adverse Event	All Doses 400 µg	
	(n = 36)	(n = 9)
chest discomfort	3	3
increased heart rate	3	1
hypotension	2	2
flushing	2	1
shortness of breath	2	0
funny taste in mouth	1	0
sensation in mouth, sinus, and chest	1	0
headache	1	0
tingling in hands	1	1
heart racing	1	1
bradycardia	1	1
lightheadedness	1	1
cough	1	0
nausea and vomiting	1	0

Figure 7

8/17


Figure 8

**Mean CVT-3146 Plasma Concentration in
Healthy Male Volunteers - Supine Position**




9/17

Figure 9




11/17

Figure 11




12/17

Figure 12




13/17

Figure 13




14/17

Figure 14



15/17

Figure 15



16/17




Figure 16




Figure 17

17/17




Figure 18